Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Liraglutide pre-filled pen in Denmark as the first country in a Scandinavian registration procedure. Approvals in Sweden and Norway are expected to follow upon finalized national reviews.

Liraglutide pre-filled pen, a GLP-1 peptide drug that will be marketed under the brand name Milmiga®, is a bioequivalent version of Victoza pre-filled pen, indicated for the treatment of type 2 diabetes. Victoza achieved sales exceeding €27 million in Scandinavia, as reported by DLMI. 

“The successful approval of Liraglutide highlights our capability to offer a diverse and comprehensive portfolio, encompassing both complex peptide injectables and small molecule oral treatments.” says Mr Lars Minor CEO of Newbury

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen

© Modular Finance, source Nordic Press Releases